Allergan-Valeant fight holds lessons for all corporate shareholders

Steven Davidoff Solomon writes for The New York Times, September 18, 2014

We are now in the world of the technical, with no real judicial rules to guide companies and activists. The Allergan bylaw fight will probably be only the first of many until the courts, or perhaps even the Securities and Exchange Commission, pronounce clearer rules.